|
注册号: Registration number: |
ChiCTR2300069776 |
|
最近更新日期: Date of Last Refreshed on: |
2023-06-24 21:57:45 |
|
注册时间: Date of Registration: |
2023-03-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
不同针刺方法干预慢性稳定性心绞痛的临床研究 |
|
Public title: |
A Study of Different Acupuncture Methods for the Treatment of Chronic Stable Angina |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
不同针刺方法干预慢性稳定性心绞痛的临床研究 |
|
Scientific title: |
A Study of Different Acupuncture Methods for the Treatment of Chronic Stable Angina |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
唐枭 |
研究负责人: |
彭志才 |
|
Applicant: |
Xiao Tang |
Study leader: |
Zhicai Peng |
|
申请注册联系人电话: Applicant telephone: |
+86 156 6348 6531 |
研究负责人电话:
Study leader's |
+86 155 2838 5250 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
464772837@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
wen_qiao1@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
重庆市永川区迎宾大道2号 |
研究负责人通讯地址: |
重庆市永川区迎宾大道2号 |
|
Applicant address: |
2 Yingbin Avenue, Yongchuan District, Chongqing |
Study leader's address: |
2 Yingbin Avenue, Yongchuan District, Chongqing |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
重庆市永川区中医院 |
||
|
Applicant's institution: |
Chongqing Yongchuan District Hospital of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
重庆市永川区中医院 |
||
|
Affiliation of the Leader: |
Chongqing Yongchuan District Hospital of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2022-032-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
重庆市永川区中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Chongqing Yongchuan District Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2022-09-26 00:00:00 | ||
|
伦理委员会联系人: |
未说明 |
||
|
Contact Name of the ethic committee: |
Not stated |
||
|
伦理委员会联系地址: |
重庆市永川区中医院 |
||
|
Contact Address of the ethic committee: |
Chongqing Yongchuan District Hospital of Traditional Chinese Medicine |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
重庆市永川区中医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chongqing Yongchuan District Hospital of Traditional Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
重庆市永川区迎宾大道2号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
2 Yingbin Avenue, Yongchuan District, Chongqing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
重庆市科卫联合中医药项目(2023QNXM053) |
||||||||||||||||||||||
|
Source(s) of funding: |
the Chongqing Science and Health Joint Medical Research Project (Grant No. 2023QNXM053) |
||||||||||||||||||||||
|
研究疾病: |
慢性稳定性心绞痛 |
||||||||||||||||||||||
|
Target disease: |
Chronic stable angina |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
本课题评价揿针和常规针刺治疗慢性稳定性心绞痛的临床疗效差异和效应特点,以期更好地指导临床实践,提高诊疗水平。 |
||||||||||||||||||||||
|
Objectives of Study: |
This trial evaluates the differences in clinical efficacy and effect characteristics between thumbtack intradermal needling and conventional acupuncture in the treatment of chronic stable angina pectoris, with a view to better guiding clinical practice and improving the level of diagnosis and treatment. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1. 孕妇及哺乳期妇女、近半年有生育要求者; 2. 合并有心血管、消化、泌尿、呼吸、血液、神经、内分泌系统等严重原发性疾病临床未能有效控制病情者; 3. 转为急性冠状动脉综合征,严重的心律失常者; 4. 伴严重精神疾病及智力障碍不能配合问卷调查者; 5. 未能控制高血压5或糖尿病5者; 6. 在过去1个月内因心血管疾病曾接受针灸治疗者; 7. 有出血倾向及皮肤病患者; 8. 过敏体质及对胶布过敏者; 9. 正在参加其他临床试验者; 10. 参与fMRI试验部分的受试者还需排除:MRI禁忌症,如体内含有金属植入物、幽闭恐惧症等。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Pregnant and breastfeeding women, those who have childbearing requirements in the past six months; 2. Combined with serious primary diseases such as cardiovascular, digestive, urinary, respiratory, blood, nervous, endocrine systems, etc., the disease cannot be effectively controlled clinically; 3. Turned into acute coronary syndrome, severe arrhythmia; 4. Those with severe mental illness and intellectual disability who cannot cooperate with the questionnaire; 5. Failure to control high blood pressure 5 or diabetes 5; 6. Those who have received acupuncture treatment due to cardiovascular disease in the past 1 month; 7. Patients with bleeding tendency and skin diseases; 8. Allergic constitution and those who are allergic to tape; 9. Those who are participating in other clinical trials; 10. Subjects participating in the fMRI trial part also need to exclude: MRI contraindications, such as metal implants in the body, claustrophobia, etc. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-01-01 00:00:00至 To 2025-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-03-31 00:00:00 至 To 2025-06-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
本研究采用分层区组随机化方法,用SAS9.1统计软件编程,按照年龄、性别进行分层,给定种子数和区组长度,按1:1比例将受试对象分为揿针组与常规针刺组,由不参与评估及统计分析的人员产生78例受试者的随机分组安排。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
In this study, using stratified group randomization method, using SAS 9.1 statistical software programming, stratified according to age and gender, the subjects into press and conventional needle group according to 1:1 ratio, 78 subjects of the randomization arrangement, and make the corresponding random envelope. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本项研究将以设盲方式实施。受试者、研究者、任何一个管理委员会、申办者实施研究的工作人员,不会获知个体受试者治疗分组的情况。 |
|
Blinding: |
This study will be conducted in a blinded manner. Subject, investigators, any management committee, and the staff member of the sponsor performing the study will not be informed of the treatment groups of individual subjects. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
通过发表期刊文章公开原始数据 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
by publication |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF表采集数据,REDCap数据平台存档管理 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
collect data by CRF, and manage data via REDCap database platform |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |